{"id":"tmc114","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1323","moleculeType":"Small molecule","molecularWeight":"547.67"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TMC114 works by inhibiting the protease enzyme, which is essential for the replication of the HIV-1 virus. This inhibition prevents the virus from producing new viral particles, thereby reducing the viral load in the body.","oneSentence":"TMC114 is a protease inhibitor used to treat HIV-1 infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:00.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in treatment-experienced adult patients"},{"name":"Treatment of HIV-1 infection in treatment-naive adult patients"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT06139796","phase":"PHASE1, PHASE2","title":"Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV","status":"WITHDRAWN","sponsor":"PENTA Foundation","startDate":"2025-02-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT03696160","phase":"PHASE3","title":"The Late Presenter Treatment Optimisation Study","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2019-03-05","conditions":"HIV/AIDS","enrollment":447},{"nctId":"NCT05642481","phase":"","title":"Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"HIV-1-infection","enrollment":16},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT03194165","phase":"","title":"Population Pharmacokinetics of Antiretroviral in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-16","conditions":"Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed","enrollment":65},{"nctId":"NCT06005610","phase":"PHASE2","title":"Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-04","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT06747507","phase":"PHASE3","title":"Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance","status":"RECRUITING","sponsor":"University of Nairobi","startDate":"2025-09-01","conditions":"HIV-1-infection","enrollment":392},{"nctId":"NCT06799650","phase":"PHASE2","title":"Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV","status":"RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2025-01-01","conditions":"HIV Seropositivity","enrollment":40},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT06787976","phase":"PHASE4","title":"Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.","status":"NOT_YET_RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-06-19","conditions":"HIV, Insomnia, Anxiety","enrollment":140},{"nctId":"NCT06907056","phase":"PHASE4","title":"Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2023-11-09","conditions":"HIV Infection","enrollment":138},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT03123848","phase":"PHASE4","title":"A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2017-04-14","conditions":"Healthy","enrollment":8},{"nctId":"NCT03227861","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2017-07-31","conditions":"HIV-1","enrollment":109},{"nctId":"NCT02578550","phase":"PHASE1","title":"A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-11","conditions":"Healthy","enrollment":126},{"nctId":"NCT04718805","phase":"PHASE1","title":"A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-01-26","conditions":"Healthy","enrollment":22},{"nctId":"NCT04661397","phase":"PHASE1","title":"A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-01-05","conditions":"Healthy","enrollment":37},{"nctId":"NCT02984852","phase":"PHASE1","title":"Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT04208061","phase":"PHASE1","title":"A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-18","conditions":"Healthy","enrollment":28},{"nctId":"NCT03675815","phase":"PHASE4","title":"Body Composition Sub-study of the D2EFT Trial","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-12-05","conditions":"HIV Infections","enrollment":155},{"nctId":"NCT02987530","phase":"PHASE3","title":"National Multicenter Trial Evaluating Two Treatments in Patients with Primary Human Immunodeficiency Virus (HIV-1) Infection","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-04-11","conditions":"HIV-1 Infection","enrollment":101},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT06676410","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2023-07-20","conditions":"HIV, HIV Infection","enrollment":40},{"nctId":"NCT01400412","phase":"PHASE2","title":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-01-17","conditions":"HIV-1 Infection","enrollment":262},{"nctId":"NCT03577470","phase":"","title":"An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2018-06-13","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":246},{"nctId":"NCT02275780","phase":"PHASE3","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-01","conditions":"HIV-1","enrollment":769},{"nctId":"NCT02735863","phase":"PHASE2","title":"ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2016-05","conditions":"HIV Infection","enrollment":30},{"nctId":"NCT04630002","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-10-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT04268472","phase":"NA","title":"Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg (\"Jonson&Jonson\", Russia)","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-06-06","conditions":"Bioequivalence","enrollment":44},{"nctId":"NCT01480713","phase":"PHASE3","title":"Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors","status":"COMPLETED","sponsor":"IrsiCaixa","startDate":"2012-05","conditions":"HIV-1 Infection","enrollment":41},{"nctId":"NCT04388904","phase":"PHASE4","title":"Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)","status":"COMPLETED","sponsor":"The Crofoot Research Center, Inc.","startDate":"2021-09-01","conditions":"HIV-1-infection","enrollment":75},{"nctId":"NCT04653194","phase":"PHASE3","title":"Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'","status":"COMPLETED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2020-09-30","conditions":"Human Immunodeficiency Virus","enrollment":36},{"nctId":"NCT02437110","phase":"PHASE1","title":"HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2019-04-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":122},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT03864406","phase":"PHASE1","title":"Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2019-06-04","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT02486133","phase":"PHASE3","title":"Dual Therapy With Boosted Darunavir + Dolutegravir","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-07","conditions":"HIV-Infection","enrollment":269},{"nctId":"NCT05463783","phase":"PHASE4","title":"Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain","status":"UNKNOWN","sponsor":"East Carolina University","startDate":"2023-03-14","conditions":"HIV Infections, Obesity","enrollment":30},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":"HIV","enrollment":60},{"nctId":"NCT05197075","phase":"PHASE1","title":"A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-03","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":15},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT01423812","phase":"PHASE4","title":"DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects","status":"COMPLETED","sponsor":"Ruth M. Rothstein CORE Center","startDate":"2012-01","conditions":"HIV","enrollment":60},{"nctId":"NCT02475915","phase":"PHASE1, PHASE2","title":"Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2015-01","conditions":"Acute HIV Infection","enrollment":15},{"nctId":"NCT03017872","phase":"PHASE4","title":"Dolutegravir and Darunavir Evaluation in Adults Failing Therapy","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2017-11-23","conditions":"HIV Infections","enrollment":831},{"nctId":"NCT04194021","phase":"","title":"Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir","status":"UNKNOWN","sponsor":"Elizabeth Glaser Pediatric AIDS Foundation","startDate":"2019-01-01","conditions":"HIV/AIDS","enrollment":871},{"nctId":"NCT04040075","phase":"PHASE4","title":"Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy","status":"TERMINATED","sponsor":"Southampton Healthcare, Inc.","startDate":"2019-07-01","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT01281813","phase":"PHASE3","title":"TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2011-08-08","conditions":"HIV-1 Infections","enrollment":145},{"nctId":"NCT05378906","phase":"PHASE1","title":"A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT02431247","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-07-06","conditions":"Immunodeficiency Virus Type 1, Human","enrollment":725},{"nctId":"NCT04425382","phase":"","title":"Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2020-03-01","conditions":"Coronavirus, COVID, Pneumonia","enrollment":400},{"nctId":"NCT03685500","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-12-04","conditions":"HIV Infections","enrollment":78},{"nctId":"NCT04901728","phase":"","title":"Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)","status":"UNKNOWN","sponsor":"University of Sussex","startDate":"2021-07-01","conditions":"HIV Infections","enrollment":118},{"nctId":"NCT02771249","phase":"PHASE1","title":"Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2016-06-03","conditions":"HIV Infected Population With Latent Tuberculosis","enrollment":37},{"nctId":"NCT03683524","phase":"PHASE4","title":"EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2018-11-19","conditions":"HIV-1 Infection","enrollment":96},{"nctId":"NCT03782142","phase":"","title":"Effect on HIV Medications on EPC Cells","status":"COMPLETED","sponsor":"Sabyasachi Sen","startDate":"2018-11-01","conditions":"AIDS","enrollment":22},{"nctId":"NCT00885495","phase":"PHASE1, PHASE2","title":"Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2009-01","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT02269917","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-03","conditions":"Human Immunodeficiency Virus Type 1","enrollment":1149},{"nctId":"NCT00260078","phase":"PHASE1, PHASE2","title":"Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT04867083","phase":"PHASE3","title":"Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-06-21","conditions":"HIV Infections","enrollment":440},{"nctId":"NCT00537394","phase":"PHASE3","title":"Optimizing Treatment for Treatment-Experienced, HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-01","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT04303299","phase":"PHASE3","title":"Fight COVID-19 Trial","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-08-19","conditions":"SARS-COV-2 Infections, COVID-19","enrollment":320},{"nctId":"NCT03447873","phase":"PHASE4","title":"Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2017-06-01","conditions":"HIV Infections","enrollment":153},{"nctId":"NCT03602690","phase":"PHASE2","title":"Evaluation of Third-line cART Regimen in Cambodia (3DICAM)","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-10-04","conditions":"HIV/AIDS","enrollment":54},{"nctId":"NCT02738502","phase":"PHASE2","title":"Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-07-06","conditions":"Maternal-fetal Infection Transmission","enrollment":91},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":"ADHD, HIV","enrollment":127},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT02499978","phase":"PHASE2, PHASE3","title":"Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2016-05","conditions":"HIV/AIDS","enrollment":""},{"nctId":"NCT04006704","phase":"PHASE1","title":"Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2019-10-10","conditions":"HIV-1","enrollment":25},{"nctId":"NCT04475120","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2020-04-15","conditions":"Covid19","enrollment":92},{"nctId":"NCT02383108","phase":"PHASE2, PHASE3","title":"Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2016-06","conditions":"HIV Infection","enrollment":318},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT04386447","phase":"PHASE2","title":"Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19","status":"WITHDRAWN","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-09-01","conditions":"Covid-19, Corona Virus Infection, SARS-CoV 2","enrollment":""},{"nctId":"NCT04435587","phase":"PHASE4","title":"Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-07-13","conditions":"Asymptomatic Infections, SARS-CoV2 Infection","enrollment":80},{"nctId":"NCT03472326","phase":"PHASE2","title":"Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2018-04-03","conditions":"HIV-1-infection","enrollment":21},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT02285478","phase":"","title":"Pharmacokinetics of Once Daily Darunavir/Ritonavir in HIV-infected Children","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-03","conditions":"Human Immunodeficiency Virus, Children","enrollment":12},{"nctId":"NCT04183738","phase":"PHASE4","title":"Inflammation and Co-Infections in D²EFT","status":"WITHDRAWN","sponsor":"Kirby Institute","startDate":"2021-02-01","conditions":"HIV-infection/Aids, Human Herpesvirus 4 Infections, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT03163277","phase":"PHASE4","title":"Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)","status":"TERMINATED","sponsor":"Giovanni Di Perri","startDate":"2017-05-15","conditions":"Hiv, Neurocognitive Dysfunction","enrollment":38},{"nctId":"NCT02577042","phase":"PHASE4","title":"Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2015-10-15","conditions":"Aging-related Inflammation in HIV-infected Patients","enrollment":42},{"nctId":"NCT03198884","phase":"","title":"A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir","status":"COMPLETED","sponsor":"Southern Illinois Healthcare Foundation","startDate":"2017-01-01","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT03472963","phase":"PHASE1","title":"Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-04-27","conditions":"HIV Infections","enrollment":35},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT01695954","phase":"PHASE1","title":"Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-05","conditions":"Hyperlipidemia, HIV","enrollment":34},{"nctId":"NCT03988452","phase":"PHASE3","title":"Nucleosides And Darunavir/Dolutegravir In Africa","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2019-07-30","conditions":"Human Immunodeficiency Virus","enrollment":465},{"nctId":"NCT03515772","phase":"","title":"Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2018-04-23","conditions":"HIV Infections, Drug Interactions, Cardiovascular Diseases","enrollment":21},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT04236453","phase":"PHASE1","title":"A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents","status":"TERMINATED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-01-23","conditions":"Healthy","enrollment":16},{"nctId":"NCT04388514","phase":"NA","title":"Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2020-04-08","conditions":"SARS-CoV-2 Respiratory Failure","enrollment":90},{"nctId":"NCT04368351","phase":"","title":"Bacteriotherapy in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2020-03-01","conditions":"COVID, Pneumonia, Diarrhea","enrollment":70},{"nctId":"NCT04366089","phase":"PHASE2","title":"Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora","status":"UNKNOWN","sponsor":"Roberto Poscia MD, PhD","startDate":"2020-03-26","conditions":"COVID, SARS-CoV 2, Pneumonia, Viral","enrollment":152}],"_emaApprovals":[],"_faersSignals":[{"count":20,"reaction":"PYREXIA"},{"count":19,"reaction":"IMMUNE RECONSTITUTION SYNDROME"},{"count":14,"reaction":"RENAL FAILURE"},{"count":13,"reaction":"DEHYDRATION"},{"count":13,"reaction":"PANCREATITIS"},{"count":12,"reaction":"DIARRHOEA"},{"count":10,"reaction":"HEPATITIS"},{"count":10,"reaction":"PNEUMONIA"},{"count":9,"reaction":"RENAL FAILURE ACUTE"},{"count":8,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"}],"_approvalHistory":[],"publicationCount":105,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Darunavir"],"phase":"phase_3","status":"active","brandName":"TMC114","genericName":"TMC114","companyName":"Tibotec Pharmaceuticals, Ireland","companyId":"tibotec-pharmaceuticals-ireland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TMC114 is a protease inhibitor used to treat HIV-1 infection. Used for Treatment of HIV-1 infection in treatment-experienced adult patients, Treatment of HIV-1 infection in treatment-naive adult patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}